The Belgian biotech Galapagos NV has announced a new strategy focused on the development of potential chimeric antigen receptor (CAR) T cells for the treatment of autoimmune diseases. If executed, the strategy would involve recalibrating a long-term relationship with Gilead Sciences Inc with whom it has been working since 2015. In separate statements on 23 March, Gilead announced the acquisition of the privately-held US biotech company Ouro Medicines Inc, and Galapagos said it is in discussions with Gilead to share the cost of developing the target company’s lead asset.
